search
Back to results

Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) (HS-ARS)

Primary Purpose

Ionizing Radiation Exposure

Status
Unknown status
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Cell therapy
Sponsored by
Pluristem Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ionizing Radiation Exposure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject was exposed or suspected to have been exposed to ionizing radiation of

    ≥1Gy and is at risk of developing HS-ARS, as assessed by the treating physician, based on REMM guidelines (see APPENDIX 1).

  2. PLX-R18 treatment can be initiated within 4 days of exposure.
  3. Aged ≥18 years.
  4. Has provided informed consent. -

Exclusion Criteria:

  1. Known active malignancy or history of malignancy within 3 years prior to screening except for successfully resected skin basal cell carcinoma or skin squamous cell carcinoma not located at the injection sites.
  2. Known active uncontrolled infection (e.g. viral, fungal, and/or bacterial)
  3. Known active infection with Hepatitis A, B, or C.
  4. Pregnancy.
  5. Known hypersensitivity to: Allogeneic stromal cells, dimethyl sulfoxid (DMSO), human serum albumin, or bovine products.
  6. In the opinion of the Investigator the subject is at high risk of developing severe allergic/hypersensitivity reactions and a resuscitation kit including epinephrine is not at hand.
  7. In the opinion of the treating physician, the subject is unsuitable for participating in the study.

    -

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    4 million PLX-R18 cells/kg-up to a maximal dose of 400 million

    Arm Description

    Outcomes

    Primary Outcome Measures

    Any Adverse Reaction

    Secondary Outcome Measures

    Recovered with no sequelae
    The subject has fully recovered from the AE with no residual effects observable.
    Recovered with sequelae
    The event resolved but the subject has sequelae, which is a condition following a consequence of a disease
    Ongoing AE
    AE is still ongoing
    Overall survival
    Overall survival

    Full Information

    First Posted
    December 17, 2018
    Last Updated
    July 27, 2020
    Sponsor
    Pluristem Ltd.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03797040
    Brief Title
    Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)
    Acronym
    HS-ARS
    Official Title
    Open-label Phase I Study to Evaluate the Safety of PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    January 2021 (Anticipated)
    Primary Completion Date
    December 2021 (Anticipated)
    Study Completion Date
    December 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Pluristem Ltd.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    The objective of the study is to evaluate the safety of intramuscular (IM) administration of PLX-R18 in subjects exposed to ionizing radiation and who are at risk of developing HS-ARS. Indication:Post-Exposure Prevention (PEP) or treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) in subjects suspected to have been exposed to ionizing radiation.
    Detailed Description
    This will be a Phase I, open-label safety study; each subject will receive two administrations of PLX-R18, 4 days apart. Each administration of PLX-R18 will contain 4 million cells/kg (up to a maximal dose of 400 million cells). The first administration should be preferably within 48 hours after suspected exposure and no later than 4 days after suspected exposure. The second administration will be provided 4 days after first administration. All subjects will be hospitalized for at least 24 hours after each administration of PLX-R18,for close monitoring.In order to minimize risks, subjects will be divided in 3 sequential cohorts: Cohort 1: 9 subjects, treated as soon as possible Cohort 2: 18 subjects, treated at least 12 hours following the first dose administered to the 9th subject Cohort 3: 33 subjects, treated at least 12 hours following the first dose administered to the 27th subject After the completion of each Cohort, stopping rules will be assessed. All subjects will receive PLX-R18 in addition to recommended care per physician discretion, based on the REMM guidelines (APPENDIX 2). The study will be comprised of 2 periods: Main study period - Subjects will be followed-up for 12 months and evaluated at the following time points after the first administration: Day 0 (first administration),Day 1, Day 2, Day 3, Day 4 (second administration), Day 5, Day 14 (2 weeks),Day 21 (3 weeks), Day 28 (4 weeks), Day 49 (7 weeks), Day 63 (9 weeks), Day 119(17 weeks), Day 182 (26 weeks), and Day 364 (52 weeks).Long-term survival follow-up -Week 52 to Week 260: During this period, patients will be followed-up for overall survival at: 104 weeks, 156 weeks, 208 weeks and 260 weeks.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Ionizing Radiation Exposure

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Sequential Assignment
    Masking
    None (Open Label)
    Enrollment
    27 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    4 million PLX-R18 cells/kg-up to a maximal dose of 400 million
    Arm Type
    Experimental
    Intervention Type
    Biological
    Intervention Name(s)
    Cell therapy
    Other Intervention Name(s)
    PLX-R18
    Intervention Description
    PLX-R18: Allogeneic ex vivo expanded placental stromal cells
    Primary Outcome Measure Information:
    Title
    Any Adverse Reaction
    Time Frame
    From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
    Secondary Outcome Measure Information:
    Title
    Recovered with no sequelae
    Description
    The subject has fully recovered from the AE with no residual effects observable.
    Time Frame
    From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
    Title
    Recovered with sequelae
    Description
    The event resolved but the subject has sequelae, which is a condition following a consequence of a disease
    Time Frame
    From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
    Title
    Ongoing AE
    Description
    AE is still ongoing
    Time Frame
    From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
    Title
    Overall survival
    Description
    Overall survival
    Time Frame
    From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subject was exposed or suspected to have been exposed to ionizing radiation of ≥1Gy and is at risk of developing HS-ARS, as assessed by the treating physician, based on REMM guidelines (see APPENDIX 1). PLX-R18 treatment can be initiated within 4 days of exposure. Aged ≥18 years. Has provided informed consent. - Exclusion Criteria: Known active malignancy or history of malignancy within 3 years prior to screening except for successfully resected skin basal cell carcinoma or skin squamous cell carcinoma not located at the injection sites. Known active uncontrolled infection (e.g. viral, fungal, and/or bacterial) Known active infection with Hepatitis A, B, or C. Pregnancy. Known hypersensitivity to: Allogeneic stromal cells, dimethyl sulfoxid (DMSO), human serum albumin, or bovine products. In the opinion of the Investigator the subject is at high risk of developing severe allergic/hypersensitivity reactions and a resuscitation kit including epinephrine is not at hand. In the opinion of the treating physician, the subject is unsuitable for participating in the study. -

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)

    We'll reach out to this number within 24 hrs